WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

The Affordable Care Act will continue to provide free preventative medications to millions of people who rely on that provision of the law.

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

About Merck’s HIV research pipeline For an overview of Merck’s HIV treatment and prevention clinical development program, please click here. Merck’s commitment to HIV For more than 35 years, Merck has ...

While a vaccine to prevent HIV still is needed, some experts say this new shot could be the next best thing.